Cart T Therapy Multiple Myeloma

Results from two early phase clinical trials suggest that a form of immunotherapy that uses genetically engineered immune cells may be highly effective in patients with advanced multiple myeloma.

Cart t therapy multiple myeloma. Both trials used car t cells that were engineered to target a protein on myeloma cells called b cell maturation antigen bcma. Right now car t cell therapy targets the cd 19 molecule on the surface of cancer cells. The trial isn t the first car based immune therapy for multiple myeloma nor the first to use a car that recognizes myeloma cells via a telltale beacon on the cancer cells known as bcma or b cell maturation antigen. Indolent b cell lymphoma mantle cell lymphoma multiple myeloma and acute myeloid leukemia.

Several other bcma car t cell therapies have been developed by researchers around the world. In multiple myeloma car t cells targeting b cell maturation antigen bcma have been investigated in a number of studies and have demonstrated important disease remitting activity. Garfall a latest clinical data bcma myeloma. This therapy targets a protein called cd229 produced on the surface of both myeloma cells and cancer stem cells the source of treatment resistant cells that may lead to disease recurrence potentially providing long lasting.

This form of immunotherapy has also shown promise as a treatment for multiple myeloma although it s not yet approved by the food and drug administration fda for that use. Where do you see car t cell therapy going in the future. In trials of patients who have relapsed after at least 3 lines of therapy including a proteasome inhibitor immunomodulator and cd38 targeting antibody the observed response rate exceeded 85 percent. The relatively new type of cancer treatment know as car t cell therapy is already being used to treat some people with leukemia and lymphoma.

A novel car t cell therapy for multiple myeloma 01 57. Abstract 8007 2018 american society of clinical oncology asco annual meeting 2018 june 1 5. A new car t cell therapy for people with multiple myeloma has been successfully created and tested in cell based experiments and a mouse model a study reported. Although most patients in the trials had good responses to the.

Although such an approval may not be far off results from a new study. After seeing promising effects of car t cell therapies in patients with relapsed refractory leukemia and lymphoma researchers began to explore their potential in relapsed refractory multiple myeloma first researchers needed to find a target for the t cells one that was detected in multiple myeloma cells. Which cancers are being looked at for the next phase of car t cell therapy clinical trials. Et al bb2121 anti bcma car t cell therapy in patients with relapsed refractory multiple myeloma.

1st european car t cell meeting paris france. Multiple myeloma remains an incurable plasma cell cancer.